PoreWise One finding · Human trial · 2014
Study title
Efficacy and Safety Results of a Drug-Free Cosmetic Fluid for Perioral Dermatitis: The Toleriane Fluide Efficacy in Perioral Dermatitis (TOLPOD) Study
- Kind of evidence
- Human trial 2014 · 51 people · patients with clinically diagnosed perioral dermatitis treated for 8 weeks at two German university dermatology departments, sex or subtype breakdown · PMID 25143674
- Measured outcome
- Skin effect
- Year
- 2014
- Who was studied
- 51 patients with clinically diagnosed perioral dermatitis treated for 8 weeks at two German university dermatology departments, sex or subtype breakdown.
- Sample size
- 51
- Measured outcome
- In an 8-week open study of 51 people with perioral dermatitis, twice-daily use of a drug-free soothing cosmetic fluid was associated with significant within-group improvement in perioral dermatitis severity (PODSI) and in itching, skin tightness and appearance over time; the improvement was better.
- Certainty
- Very low
- Who was measured
- Gentle, drug-free cosmetic or emollient-type skincare as low-risk supportive care for perioral dermatitis, the efficacy of any specific skincare active, or a substitute for medical treatment.
- Study limits
- Open-label, non-randomized, non-blinded single-arm study compared with a non-concurrent historical vehicle group, stopping the triggering product, or natural resolution. A 2022 systematic review of perioral dermatitis found low to very low certainty evidence, all for drug interventions.
Where it comes from
- Efficacy and Safety Results of a Drug-Free Cosmetic Fluid for Perioral Dermatitis: The Toleriane Fluide Efficacy in Perioral Dermatitis (TOLPOD) Study
Published by Annals of Dermatology (Ehmann L et al., 2014) · Last checked 2026-11-10
Skin concerns studied
Other findings on the same ingredient or concern
- Skin effectEfficacy of a skin care cream with TRPV1 inhibitor 4-t-butylcyclohexanol in the topical therapy of perioral dermatitis
In 48 people with perioral dermatitis, a skin care cream containing the TRPV1 inhibitor 4-t-butylcyclohexanol significantly reduced perioral dermatitis severity scores, subjective numerical ratings, transepidermal water loss, erythema and improved quality of life over 8 weeks.
Human trial · 2020 · 48 people · patients with perioral dermatitis · People with perioral dermatitis using the skin care cream for 8 weeks. · Open-label, non-blinded and uncontrolled. A systematic review of perioral dermatitis reports low to very low certainty evidence, with drug interventions and trigger avoidance as the mainstay; a skin care cream is management.